{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:01:36Z","timestamp":1794812496990,"version":"4.9.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baseline clinical characteristics and treatment courses. We retrospectively evaluated cases of PTCL treated with CHOP-based chemotherapy that had tumors sequenced by the Memorial Sloan Kettering Integrated Mutational Profiling of Actionable Cancer Targets next-generation sequencing panel to identify variables correlating with inferior survival. We identified 132 patients who met these criteria. Clinical factors correlating with an increased risk of progression (by multivariate analysis) included advanced-stage disease and bone marrow involvement. The only somatic genetic aberrancies correlating with inferior progression-free survival (PFS) were TP53 mutations and TP53\/17p deletions. PFS remained inferior when stratifying by TP53 mutation status, with a median PFS of 4.5\u00a0months for PTCL with a TP53 mutation (n\u00a0= 21) vs 10.5\u00a0months for PTCL without a TP53 mutation (n\u00a0= 111). No TP53 aberrancy correlated with inferior overall survival (OS). Although rare (n\u00a0= 9), CDKN2A-deleted PTCL correlated with inferior OS, with\u00a0a median of 17.6\u00a0months vs 56.7\u00a0months for patients without CDKN2A deletions. This retrospective study suggests that patients with PTCL with TP53 mutations experience inferior PFS when treated with curative-intent chemotherapy, warranting prospective confirmation.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009953","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T08:50:33Z","timestamp":1681980633000},"page":"5172-5186","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["<i>TP53<\/i>\n                    mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1514-1095","authenticated-orcid":false,"given":"William T.","family":"Johnson","sequence":"first","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivetha","family":"Ganesan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-2502","authenticated-orcid":false,"given":"Zachary D.","family":"Epstein-Peterson","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5170","authenticated-orcid":false,"given":"Robert N.","family":"Stuver","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine R.","family":"Maccaro","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Galasso","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufer","family":"Khan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-6163","authenticated-orcid":false,"given":"Umut","family":"Aypar","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-7114","authenticated-orcid":false,"given":"Natasha E.","family":"Lewis","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey M.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9500-1804","authenticated-orcid":false,"given":"Paul","family":"Hamlin","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Caron","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Straus","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Intlekofer","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"},{"name":"5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-9463","authenticated-orcid":false,"given":"Connie","family":"Lee Batlevi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-5810","authenticated-orcid":false,"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette N.","family":"Owens","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Lue","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-1298","authenticated-orcid":false,"given":"Santosha A.","family":"Vardhana","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"},{"name":"5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus D.","family":"Schultz","sequence":"additional","affiliation":[{"name":"7Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[{"name":"8Department of Pathology, Molecular Diagnostic Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"20","key":"2023091115540685600_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2023091115540685600_bib2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023091115540685600_bib3","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A\u00a0prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2023091115540685600_bib4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2023091115540685600_bib5","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2023091115540685600_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajh.25450","article-title":"Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma","volume":"94","author":"Maura","year":"2019","journal-title":"Am J Hematol"},{"issue":"9","key":"2023091115540685600_bib7","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2023091115540685600_bib8","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"10168","key":"2023091115540685600_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"18","key":"2023091115540685600_bib10","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2023091115540685600_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"25","key":"2023091115540685600_bib12","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023091115540685600_bib13","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"issue":"9","key":"2023091115540685600_bib14","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"2023091115540685600_bib15","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2020.262659","article-title":"CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)","volume":"106","author":"Maura","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"2023091115540685600_bib16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-020-01093-1","article-title":"STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma","volume":"35","author":"Lobello","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2023091115540685600_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41379-019-0279-8","article-title":"Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified","volume":"33","author":"Laginestra","year":"2020","journal-title":"Mod Pathol"},{"issue":"12","key":"2023091115540685600_bib18","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"15","key":"2023091115540685600_bib19","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023091115540685600_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2023091115540685600_bib21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2015.357","article-title":"Recurrent activating mutations of CD28 in peripheral T-cell lymphomas","volume":"30","author":"Rohr","year":"2016","journal-title":"Leukemia"},{"issue":"269","key":"2023091115540685600_bib22","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"2023091115540685600_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"3","key":"2023091115540685600_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"issue":"6","key":"2023091115540685600_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"2023091115540685600_bib26","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.15859","article-title":"Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas","volume":"186","author":"Ellin","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"2023091115540685600_bib27","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2023091115540685600_bib28","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2023091115540685600_bib29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A\u00a0targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"2023091115540685600_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"2023091115540685600_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13073-016-0393-x","article-title":"3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets","volume":"9","author":"Gao","year":"2017","journal-title":"Genome Med"},{"issue":"17","key":"2023091115540685600_bib32","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2023091115540685600_bib33","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2020009530","article-title":"Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options","volume":"138","author":"Malcikova","year":"2021","journal-title":"Blood"},{"key":"2023091115540685600_bib34","doi-asserted-by":"crossref","first-page":"610820","DOI":"10.3389\/fonc.2020.610820","article-title":"TP53 mutations in acute myeloid leukemia: still a daunting challenge?","volume":"10","author":"Molica","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2023091115540685600_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"2023091115540685600_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-018-0089-0","article-title":"Integrated DNA\/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay","volume":"8","author":"Intlekofer","year":"2018","journal-title":"Blood Cancer J"},{"issue":"24","key":"2023091115540685600_bib37","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","article-title":"Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers","volume":"5","author":"Rodr\u00edguez","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2023091115540685600_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-021-00224-3","article-title":"Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas","volume":"10","author":"Yoon","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"2023091115540685600_bib39","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"issue":"suppl 2","key":"2023091115540685600_bib40","article-title":"The combination of duvelisib and romidepsin (Dr) is highly active against relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results","volume":"39","author":"Horwitz","year":"2021","journal-title":"Hematol Oncol"},{"issue":"suppl 2","key":"2023091115540685600_bib41","article-title":"First-in-human study of the Ezh1 and Ezh2 dual inhibitor valemetostat tosylate (Ds-3201b) in patients with relapsed or refractory non-Hodgkin lymphomas","volume":"39","author":"Ishitsuka","year":"2021","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2023091115540685600_bib42","first-page":"2456-2456","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: results of an interim analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood"},{"issue":"26","key":"2023091115540685600_bib43","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A\u00a0phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023091115540685600_bib44","first-page":"466-466","article-title":"A\u00a0phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2023091115540685600_bib45","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5172\/2077105\/blooda_adv-2023-009953-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5172\/2077105\/blooda_adv-2023-009953-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T22:31:34Z","timestamp":1702247494000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/5172\/495387\/TP53-mutations-identify-high-risk-events-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":45,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009953","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}